Free Trial

BioSyent (CVE:RX) Stock Price Passes Above 50-Day Moving Average - What's Next?

BioSyent logo with Medical background

Shares of BioSyent Inc. (CVE:RX - Get Free Report) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$10.75 and traded as high as C$10.77. BioSyent shares last traded at C$10.77, with a volume of 3,490 shares.

BioSyent Stock Performance

The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The company has a market cap of C$133.82 million, a PE ratio of 18.99 and a beta of 0.93. The stock has a 50 day moving average price of C$10.80 and a 200 day moving average price of C$11.06.

About BioSyent

(Get Free Report)

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

Featured Stories

Should You Invest $1,000 in BioSyent Right Now?

Before you consider BioSyent, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.

While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Oil Spikes Amid Rising Warfare: 3 Stocks to Watch Now
Palantir at All-Time Highs: Take Profits or Hold the Line?
3 Tech Stocks Insiders Are Buying: Speculative Plays for June

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines